Research map: A Framework for Risk-Based Implementation of Combination Therapy in CKD

Back to the article

Papers in this map

  1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Paul E. Stevens · 2024 · 8239 citations · Cited by this paper
  2. ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome · Nisha Bansal · 2026 · Cites this paper
  3. A Patient's Perspective on Arteriovenous Fistula Care and Far-Infrared Radiation Arteriovenous Fistula Therapy · 2026 · Related
  4. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes · George L. Bakris · 2020 · 2886 citations · Cited by this paper
  5. A Qualitative Study of Patients, Caregivers, and Providers on Barriers to Kidney Re-Transplantation Following Graft Loss · 2026 · Related
  6. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure · Theresa A. McDonagh · 2023 · 2438 citations · Cited by this paper
  7. From Risk Determinants to Clinical Action · 2026 · Related
  8. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  9. Fluid Tolerance in Acute Kidney Injury · 2026 · Related
  10. Development and Validation of the American Heart Association’s PREVENT Equations · Sadiya S. Khan · 2023 · 1163 citations · Cited by this paper
  11. Sequential Biomarker Testing in Kidney Transplant Surveillance · 2026 · Related
  12. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial · Alexandre Mebazaa · 2022 · 1101 citations · Cited by this paper
  13. IgA Nephropathy Across the Age Spectrum · 2026 · Related
  14. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure · Navdeep Tangri · 2016 · 747 citations · Cited by this paper
  15. Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children · 2026 · Related
  16. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria · Brendon Lange Neuen · 2023 · 342 citations · Cited by this paper
  17. The Sexual Dimorphism in Kidney Potassium Handling · 2026 · Related
  18. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial · Richard A. Lafayette · 2023 · 329 citations · Cited by this paper
  19. Clonal Hematopoiesis of Indeterminate Potential and Kidney Failure in Chronic Kidney Disease · 2026 · Related
  20. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial · Brad H. Rovin · 2023 · 301 citations · Cited by this paper
  21. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials · Brendon L. Neuen · 2022 · 280 citations · Cited by this paper
  22. Relationship between polypharmacy and underprescribing · Mascha A. J. Kuijpers · 2007 · 256 citations · Cited by this paper
  23. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis · Peter R Rossing · 2022 · 215 citations · Cited by this paper
  24. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease · Lili Chan · 2021 · 186 citations · Cited by this paper
  25. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy · Peter R Rossing · 2021 · 169 citations · Cited by this paper
  26. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials · Ellen M. Apperloo · 2024 · 156 citations · Cited by this paper
  27. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis · Brendon Lange Neuen · 2024 · 152 citations · Cited by this paper
  28. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial · Hiddo J.L. Heerspink · 2023 · 147 citations · Cited by this paper
  29. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) · Brad H. Rovin · 2025 · 144 citations · Cited by this paper
  30. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries · Ruth J Webster · 2015 · 130 citations · Cited by this paper
  31. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial · Richard E. Pratley · 2024 · 125 citations · Cited by this paper
  32. Quality of Chronic Kidney Disease Management in Canadian Primary Care · Aminu K. Bello · 2019 · 103 citations · Cited by this paper
  33. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD · Niels Jongs · 2022 · 92 citations · Cited by this paper
  34. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease · Robert J. Nee · 2022 · 78 citations · Cited by this paper
  35. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria · Brendon Lange Neuen · 2025 · 71 citations · Cited by this paper
  36. Polypharmacy in Patients with CKD · Ilse J. Oosting · 2024 · 70 citations · Cited by this paper
  37. Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial · Navdeep Tangri · 2024 · 38 citations · Cited by this paper
  38. From progression to remission: a new paradigm for success in chronic kidney disease · Navdeep Tangri · 2025 · 33 citations · Cited by this paper
  39. Frailty, Multimorbidity, and Polypharmacy · Kaitlin J. Mayne · 2024 · 31 citations · Cited by this paper

Source: OpenAlex (CC0)